tiprankstipranks
Artemis Medicare Services Ltd. (IN:ARTEMISMED)
:ARTEMISMED
India Market
Want to see IN:ARTEMISMED full AI Analyst Report?

Artemis Medicare Services Ltd. (ARTEMISMED) AI Stock Analysis

2 Followers

Top Page

IN:ARTEMISMED

Artemis Medicare Services Ltd.

(ARTEMISMED)

Select Model
Select Model
Select Model
Neutral 65 (OpenAI - 5.2)
Rating:65Neutral
Price Target:
₹268.00
▼(-2.97% Downside)
Action:DowngradedDate:02/04/26
The score is primarily supported by strong financial performance (growth, improving margins, solid cash generation, and moderate leverage). This is offset by weak technicals showing a pronounced downtrend and negative momentum, and by a relatively high P/E with a very low dividend yield.
Positive Factors
Multi-year revenue growth
A 68% revenue increase over five years signals durable demand for Artemis's hospital services and successful geographic/service expansion. Sustained top-line growth supports scale economics, better fixed-cost absorption and long-term investment in facilities and specialty care capabilities.
Negative Factors
EBITDA margins below industry leaders
Persistently lower EBITDA margins versus leading peers indicate structural efficiency or scale disadvantages. This can limit reinvestment capacity and pricing flexibility, making it harder to compete for high-margin specialties and to absorb cost inflation over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue growth
A 68% revenue increase over five years signals durable demand for Artemis's hospital services and successful geographic/service expansion. Sustained top-line growth supports scale economics, better fixed-cost absorption and long-term investment in facilities and specialty care capabilities.
Read all positive factors

Artemis Medicare Services Ltd. (ARTEMISMED) vs. iShares MSCI India ETF (INDA)

Artemis Medicare Services Ltd. Business Overview & Revenue Model

Company Description
Artemis Medicare Services Limited manages and operates multi specialty hospitals in India and internationally. The company offers medical and surgical intervention; and inpatient and outpatient services. It also operates Artemis Hospital, a 541 be...
How the Company Makes Money
Artemis Medicare Services Ltd. generates revenue primarily through its medical services offered at its hospitals, including consultation fees, diagnostics, surgical procedures, inpatient and outpatient care, pharmacy sales, and laboratory testing....

Artemis Medicare Services Ltd. Financial Statement Overview

Summary
Strong multi-year revenue growth (+68% over five years) and meaningful profitability improvement (net margin up to 9% from 1% in 2021). Balance sheet leverage is moderate and improving (debt-to-equity down to 0.35; equity ratio 62%), and cash generation is solid (operating cash flow to net income 1.76; free cash flow up 44%), though EBITDA margin is still below industry leaders and net debt has fluctuated.
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue10.02B9.37B8.79B7.37B5.53B4.08B
Gross Profit2.27B2.23B1.78B1.04B954.40M371.67M
EBITDA1.67B1.52B1.25B1.01B713.53M359.53M
Net Income949.45M826.26M491.41M385.98M318.14M64.86M
Balance Sheet
Total Assets14.26B13.57B9.72B9.05B7.10B6.00B
Cash, Cash Equivalents and Short-Term Investments3.48B3.96B612.05M509.42M276.98M311.20M
Total Debt2.79B2.90B3.20B2.86B2.01B1.47B
Total Liabilities5.38B5.14B5.17B4.97B3.48B2.78B
Stockholders Equity8.83B8.38B4.48B4.03B3.59B3.20B
Cash Flow
Free Cash Flow136.32M524.65M363.01M-337.68M-573.20M-162.62M
Operating Cash Flow804.83M1.46B1.09B1.13B515.80M182.39M
Investing Cash Flow-681.67M-3.85B-891.04M-1.58B-1.08B-378.47M
Financing Cash Flow-270.77M2.67B-41.48M521.82M528.37M271.62M

Artemis Medicare Services Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price276.20
Price Trends
50DMA
229.54
Positive
100DMA
248.81
Negative
200DMA
245.82
Negative
Market Momentum
MACD
-0.41
Negative
RSI
52.15
Neutral
STOCH
84.35
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ARTEMISMED, the sentiment is Neutral. The current price of 276.2 is above the 20-day moving average (MA) of 224.51, above the 50-day MA of 229.54, and above the 200-day MA of 245.82, indicating a neutral trend. The MACD of -0.41 indicates Negative momentum. The RSI at 52.15 is Neutral, neither overbought nor oversold. The STOCH value of 84.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ARTEMISMED.

Artemis Medicare Services Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
₹39.47B42.270.16%12.97%29.45%
65
Neutral
₹273.07B114.0126.29%-13.63%
64
Neutral
₹37.84B25.060.96%8.53%21.02%
61
Neutral
₹719.29B86.120.11%15.99%24.81%
61
Neutral
₹102.15B60.350.21%18.95%9.30%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
₹17.57B310.390.59%4.93%-75.50%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:ARTEMISMED
Artemis Medicare Services Ltd.
249.35
-11.73
-4.49%
IN:FORTIS
Fortis Healthcare Ltd.
952.75
273.35
40.23%
IN:INDRAMEDCO
Indraprastha Medical Corporation Limited
412.75
19.42
4.94%
IN:KIMS
Krishna Institute of Medical Sciences Limited
682.45
21.55
3.26%
IN:METROPOLIS
Metropolis Healthcare Ltd.
492.70
68.30
16.09%
IN:SHALBY
Shalby Ltd.
162.65
-23.60
-12.67%

Artemis Medicare Services Ltd. Corporate Events

Artemis Medicare Schedules Mumbai Investor and Analyst Meet for February 25
Feb 19, 2026
Artemis Medicare Services Ltd. has scheduled a physical investor and analyst meeting in Mumbai on February 25, 2026, comprising one-on-one and group interactions with a wide range of domestic institutional investors and advisory firms. The company...
Artemis Medicare Publishes Q3 and 9M FY26 Earnings Call Transcript
Feb 9, 2026
Artemis Medicare Services Ltd. has released the transcript of its earnings conference call for the third quarter and nine-month period of FY26, held on February 3, 2026, where management discussed the company’s operational and financial perf...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 04, 2026